As of 2026-03-31, Zepbound（替尔泊肽，减重）'s data on the DeepSeek platform in the 医疗保健 category shows: The overall mention rate is 0.00%, above the industry average by 0.0 percentage points, showing notable performance. The first mention rate is only 0.00%, it is recommended to enhance first-position exposure in AI model responses. Negative mention rate (0.00%) has exceeded positive (0.00%), it is recommended to immediately initiate reputation repair. Among 6 competitors in the same category, Zepbound（替尔泊肽，减重）'s overall mention rate surpasses 0 brands. AIGeo recommends combining the above data to formulate targeted brand monitoring strategies to further enhance brand visibility and reputation in the AI search ecosystem.
Zepbound（替尔泊肽，减重）'s Mention Rate is 0.00%, lower than 0.6% of competitors
Zepbound（替尔泊肽，减重）'s First Mention is 0.00%, lower than 0.9% of competitors
Zepbound（替尔泊肽，减重）'s Preferred Rate is 0.00%, lower than 100.0% of competitors
Zepbound（替尔泊肽，减重）'s Positive Rate is 0.00%, lower than 8.9% of competitors
Zepbound（替尔泊肽，减重）'s Negative Rate is 0.00%, higher than 96.3% of competitors
| Competitor | Mention Rate | First Mention | Preferred Rate | Positive Rate | Negative Rate | Actions |
|---|---|---|---|---|---|---|
| DDupixent（度普利尤单抗） | 0% | 0% | 0% | 0% | 0% | View Details |
| MMounjaro（替尔泊肽，降糖） | 0% | 0% | 0% | 0% | 0% | View Details |
| OOzempic（司美格鲁肽，降糖） | 0% | 0% | 0% | 0% | 0% | View Details |
| WWegovy（司美格鲁肽，减重） | 0% | 0% | 0% | 0% | 0% | View Details |
| BBiktarvy（比克恩丙诺片，HIV） | 0% | 0% | 0% | 0% | 0% | View Details |
| EEliquis（阿哌沙班，抗凝） | 0% | 0% | 0% | 0% | 0% | View Details |
| ZZepbound（替尔泊肽，减重） (Current Brand) | 0% | 0% | 0% | 0% | 0% | View Details |
